Biohaven Ltd.

Biohaven Ltd.

BHVN·NYSE

$10.81

+6.7%
HealthcareBiotechnology

Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.

At a Glance

Live Snapshot
Market Cap$1.14B
EPS-6.8600
P/E Ratio-1.58
Earnings Date08/10/2026

bhvn

Income Before Tax

Last Annual Value

-737.38M

3-Year CAGR

-9%

5-Year CAGR

-44%

10-Year CAGR

-3%

Biohaven Ltd.

Biohaven Ltd. Competitors Analysis of Income Before Tax

BHVN · NYSE
CompanyIncome Before Tax
CAGR 3Y
CAGR 5Y
CAGR 10Y
BHVN logo
Biohaven Ltd.
NYSE:BHVN
-737.38M
N/AN/AN/A 
-412.69M
N/AN/AN/A
IMNM logo
Immunome, Inc.
NASDAQ:IMNM
-212.39M
N/AN/AN/A
-299.62M
N/AN/AN/A
-75.27M
N/AN/AN/A
-377.82M
N/AN/AN/A
554.00K
N/AN/AN/A
-258.80M
N/AN/AN/A
Biohaven Ltd.

Biohaven Ltd. Fair Value Envelope

BHVN · NYSE

Our analysis suggests that BHVN has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $10.81, this represents a potential HIDDEN relative to our calculated worth for Biohaven Ltd..

Intrinsic Value
Current Price: $10.81